Your browser doesn't support javascript.
loading
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou, Qing; Chen, Ming; Jiang, Ou; Pan, Yi; Hu, Desheng; Lin, Qin; Wu, Gang; Cui, Jiuwei; Chang, Jianhua; Cheng, Yufeng; Huang, Cheng; Liu, Anwen; Yang, Nong; Gong, Youling; Zhu, Chuan; Ma, Zhiyong; Fang, Jian; Chen, Gongyan; Zhao, Jun; Shi, Anhui; Lin, Yingcheng; Li, Guanghui; Liu, Yunpeng; Wang, Dong; Wu, Rong; Xu, Xinhua; Shi, Jianhua; Liu, Zhihua; Cui, Na; Wang, Jingru; Wang, Qiang; Zhang, Ran; Yang, Jason; Wu, Yi-Long.
Affiliation
  • Zhou Q; Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Chen M; The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China; Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Jiang O; The Second People's Hospital of Neijiang, Neijiang, China.
  • Pan Y; Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Hu D; Hubei Cancer Hospital, Wuhan, China.
  • Lin Q; The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • Wu G; Cancer Centre, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cui J; The First Hospital of Jilin University, Changchun, China.
  • Chang J; Fudan University Cancer Centre, Shanghai, China; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Centre, Shenzhen, China.
  • Cheng Y; Qilu Hospital of Shandong University, Jinan, China.
  • Huang C; Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou, China.
  • Liu A; The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yang N; Hunan Cancer Hospital, Changsha, China.
  • Gong Y; West China Hospital of Sichuan University, Chengdu, China.
  • Zhu C; Chongqing University Three Gorges Hospital, Chongqing, China.
  • Ma Z; The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Fang J; Beijing Cancer Hospital, Beijing, China.
  • Chen G; Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhao J; Beijing Cancer Hospital, Beijing, China.
  • Shi A; Beijing Cancer Hospital, Beijing, China.
  • Lin Y; Cancer Hospital of Shantou University Medical College, Shantou, China.
  • Li G; Xinqiao Hospital of Army Medical University, Chongqing, China.
  • Liu Y; The First Hospital of China Medical University, Shenyang, China.
  • Wang D; Army Medical Centre of PLA, Chongqing, China.
  • Wu R; Shengjing Hospital of China Medical University, Shenyang, China.
  • Xu X; The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, China.
  • Shi J; Linyi Cancer Hospital, Linyi, China.
  • Liu Z; Jiangxi Cancer Hospital, Nanchang, China.
  • Cui N; CStone Pharmaceuticals Suzhou, Shanghai, China.
  • Wang J; CStone Pharmaceuticals Suzhou, Shanghai, China.
  • Wang Q; CStone Pharmaceuticals Suzhou, Shanghai, China.
  • Zhang R; CStone Pharmaceuticals Suzhou, Shanghai, China.
  • Yang J; CStone Pharmaceuticals Suzhou, Shanghai, China.
  • Wu YL; Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: syylwu@live.cn.
Lancet Oncol ; 23(2): 209-219, 2022 02.
Article in En | MEDLINE | ID: mdl-35038429
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Chemoradiotherapy / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Chemoradiotherapy / Immune Checkpoint Inhibitors / Lung Neoplasms Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2022 Type: Article